N6 -Methyladenosine and Rheumatoid Arthritis: A Comprehensive Review

Rheumatoid arthritis (RA), one of the most common autoimmune diseases, is characterized by immune cell infiltration, fibroblast-like synovial cell hyperproliferation, and cartilage and bone destruction. To date, numerous studies have demonstrated that immune cells are one of the key targets for the treatment of RA. N-6-methyladenosine (m(6)A) is the most common internal modification to eukaryotic mRNA, which is involved in the splicing, stability, export, and degradation of RNA metabolism. m(6)A methylated-related genes are divided into writers, erasers, and readers, and they are critical for the regulation of cell life. They play a significant role in various biological processes, such as virus replication and cell differentiation by controlling gene expression. Furthermore, a growing number of studies have indicated that m(6)A is associated with the occurrence of numerous diseases, such as lung cancer, bladder cancer, gastric cancer, acute myeloid leukemia, and hepatocellular carcinoma. In this review, we summarize the history of m6A research and recent progress on RA research concerning m(6)A enzymes. The relationship between m(6)A enzymes, immune cells, and RA suggests that m(6)A modification offers evidence for the pathogenesis of RA, which will help in the development of new therapies for RA.

Automated summary

Rheumatoid arthritis is characterized by immune cell infiltration and destruction of cartilage and bone. Studies have shown that m(6)A modification is related to the pathogenesis of RA, providing evidence for the development of new therapies. The relationship between m(6)A enzymes, immune cells, and RA is important for understanding and treating this autoimmune disease.